Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Raised to $37.00 at Bank of America
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its price objective hoisted by Bank of America from $29.00 to $37.00 in a report published on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. A number of other research firms have also issued reports on ARWR. Citigroup assumed coverage […]
More Stories
Airports of Thailand Public Company Limited (OTCMKTS:AIPUY) Plans Dividend Increase – $0.16 Per Share
Airports of Thailand Public Company Limited (OTCMKTS:AIPUY – Get Free Report) announced a dividend on Saturday, November 23rd,NASDAQ Dividends reports....
Corning Natural Gas (OTCMKTS:CNIG) vs. Centuri (NYSE:CTRI) Financial Comparison
Centuri (NYSE:CTRI – Get Free Report) and Corning Natural Gas (OTCMKTS:CNIG – Get Free Report) are both utilities companies, but...
Critical Analysis: Lucas GC (NASDAQ:LGCL) versus Sangoma Technologies (NASDAQ:SANG)
Institutional & Insider Ownership 39.7% of Sangoma Technologies shares are owned by institutional investors. 14.0% of Sangoma Technologies shares are...
Americans Need $5.3 Million Net Worth to Be Considered Financially Successful: Survey
By Naveen Athrappully Americans have high expectations of what it means to be financially successful but many of them do...
2 Key Congressional Races Still Uncalled in California
By Kimberly Hayek Republicans have secured a trifecta in the November general election, taking control of the Oval Office, House,...
Hyundai Recalls 145,000 Hybrids Over Potential Battery Charging Issue
By Wim De Gent South Korean automaker Hyundai is recalling over 145,000 hybrid electric vehicles in the United States over...